In a significant strategic move, pharmaceutical giant Johnson & Johnson has announced a definitive agreement to acquire Ambrx Biopharma, a pioneering cancer drug developer, for an impressive $2 billion in cash. This acquisition, revealed on the first day of the annual JPMorgan…
